Objectives: To investigate the long-term safety and efficacy of a treatment switch to dual ART with atazanavir/ ritonavir ! lamivudine versus continuing a standard regimen with atazanavir/ritonavir ! 2NRTI in virologically suppressed patients.
Introduction
In recent years, drug reduction strategies to mono/dual therapies in HIV-infected patients have been investigated in order to improve long-term ART tolerability and to reduce costs while maintaining virological efficacy. [1] [2] [3] Dual therapies combining a boosted PI with lamivudine have been the most intensively investigated treatments, both in naive and in virologically suppressed patients. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] The combination of atazanavir/ritonavir ! lamivudine has shown promising results in virologically suppressed patients: two randomized studies, SALT and ATLAS-M, demonstrated non-inferior efficacy of a treatment switch to atazanavir/ritonavir ! lamivudine when compared with a standard atazanavir/ ritonavir-based triple therapy after a 48 week follow-up. 8, 9 In ATLAS-M, atazanavir/ritonavir ! lamivudine even showed superior efficacy over the comparator arm at the primary study endpoint and a benefit in terms of evolution of renal function. 8 It is important to investigate whether these favourable results obtained at 48 weeks persist at longer durations. The 96 week data of SALT trial have confirmed the long-term non-inferior efficacy of treatment simplification to atazanavir/ritonavir ! lamivudine with no significant benefit in terms of tolerability over triple therapy. 10 Here, we report the final 96 week efficacy and safety data of the ATLAS-M trial, investigating treatment simplification to atazanavir/ritonavir ! lamivudine versus continuing the baseline regimen in patients who are virologically suppressed under an atazanavir/ritonavir-based triple therapy. We also report results of patients' neurocognitive performance, bone mineral density and body fat distribution changes as well as the evolution of peripheral blood HIV-1-DNA levels at 96 weeks in the two study arms.
Methods

Study design, patients and procedures
The design of the ATLAS-M trial has been reported elsewhere. 8 Briefly, ATLAS-M is a 96 week open-label, randomized, non-inferiority trial comparing a treatment switch to 300 mg of atazanavir boosted with 100 mg of ritonavir once daily plus 300 mg of lamivudine once daily (atazanavir/ ritonavir ! lamivudine arm) with continuation of a standard triple-therapy regimen with 300 mg of atazanavir boosted with 100 mg of ritonavir once daily plus two NRTIs (atazanavir/ritonavir ! 2NRTI arm) in virologically suppressed patients.
Adult (.18 years old), HIV-1-infected patients on an antiretroviral regimen including atazanavir/ritonavir ! 2NRTI from at least 3 months, with HIV-RNA ,50 copies/mL and CD4 .200 cells/mm 3 from at least 6 months, no previous virological failure on or resistance to atazanavir and/or lamivudine, no previous exposure to mono/dual therapies and no HBV coinfection were randomized 1:1 at baseline to atazanavir/ritonavir ! lamivudine (study arm) or to continue the standard triple therapy (atazanavir/ ritonavir ! 2NRTI arm). The study was powered to demonstrate noninferior efficacy with a lower margin of 12% of the study regimen versus the control arm at the primary study outcome: absence of treatment failure at 48 weeks in the ITT exposed population. 8 Follow-up study visits were planned at weeks 4 and 12 and then every 12 weeks until week 96, monitoring physical examination, routine laboratory tests (HIV-RNA, CD4 count, blood chemistry, urinalysis) and treatment adherence (on a 0-100 visual analogue scale).
14 At baseline, week 48 and week 96, whole body, lumbar and hip dualenergy X-ray absorptiometry (DEXA) scans was performed in a subgroup of patients. Bone metabolism biomarkers (25-OH vitamin D, parathyroid hormone, osteocalcin, calcitonin, bone alkaline phosphatase) were also assessed at the same timepoints. Osteopenia and osteoporosis were defined according to standard criteria. 15 Body fat distribution was assessed by measuring total, limb and trunk fat/lean mass. Moreover, a comprehensive neuropsychological examination was also performed at baseline, week 48 and week 96. Exclusion criteria for this substudy were: active psychiatric disorders/alcoholism or drug abuse, and linguistic difficulties for non-native patients.
The following cognitive domains were investigated: Verbal Learning (Immediate and Delayed Recall of Rey's words), Attention and Working Memory (WAIS digit span and WAIS digit symbol), Language (Fluency test), and Fine Motor Skills (Grooved Pegboard Test). Individual scores on each cognitive test were transformed into Z scores and averaged to calculate a composite domain-specific Z score; cognitive impairment was defined according to Frascati criteria. 16 Total HIV-DNA was quantified in whole blood at baseline, and after 48 and 96 weeks, using a TaqMan real-time PCR technique, as previously described. 17 This assay takes both integrated and non-integrated HIV-DNA forms into account. Results were expressed as the log 10 -transformed HIV-DNA copies/10 6 leucocytes to normalize the distribution.
Treatment failure was defined by any of the following: virological failure, any treatment modification or discontinuation, loss to follow-up, consent withdrawal, progression to AIDS, or death from any cause. Virological failure was defined as the first of two consecutive HIV-RNA levels .50 copies/mL or a single level .1000 copies/mL. Viral blips were defined as a transient HIV-RNA level .50 copies/mL preceded and followed by viral loads ,50 copies/ mL without any treatment change. Genotypic resistance testing and measurement of atazanavir plasma levels through a validated HPLC method 18 were performed on plasma samples at the time of virological failure.
The evaluation of the proportion of patients without treatment failure at week 96 was a secondary study endpoint. Analysis of the efficacy endpoint was performed both on the ITT exposed (ITT-e) population and the PP population. In addition, FDA snapshot analyses of treatment efficacy (success " any patient in study with an HIV-RNA ,50 copies/mL in the time window + 4 weeks) were carried out at 96 weeks in both the ITT-e and PP populations. The non-inferiority margin for the comparison of atazanavir/ritonavir ! lamivudine versus atazanavir/ritonavir ! 2NRTI was set at #12%. Superiority was assessed post hoc. Other secondary endpoints included the development of virological failure and drug resistance, occurrence of clinical and laboratory adverse events, changes in CD4 cell count, HIV-DNA, blood lipid levels and renal function, and self-reported adherence from baseline to week 96.
Ethics
The protocol was approved by the Ethics Committees of each participating centre and all procedures were performed in accordance with the Declaration of Helsinki. Patients provided written informed consent to study participation before enrolment. The study was registered with ClinicalTrials.gov, number NCT01599364.
Statistical analysis
Descriptive statistics were used to describe the baseline characteristics of patients. Categorical variables were compared using the v 2 test or Fisher's exact test, as appropriate. Continuous variables were compared using the Student's t-test or the Mann-Whitney U-test if they were normally or nonnormally distributed, respectively. Only P values 0.05 were considered to be significant. All analyses were performed using the SPSS version 18.0 software package (SPSS Inc., Chicago, IL, USA).
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Results
Patient characteristics
Overall, 275 patients were screened for study participation and 266 patients were randomized, 133 to each study arm. Patient disposition at 96 weeks is illustrated in Figure 1 . Baseline patients' characteristics have been described previously. 8 Briefly, 79.7%
(n " 212) of patients were male with a median age of 44 years (IQR 36-50); 10.5% (n " 28) were HCV coinfected and 12.8% (n " 34) reported a previous AIDS-defining event. At baseline, patients had HIV-RNA ,50 copies/mL from a median of 22.0 months .0) with a median CD4 count of 617 cells/mm . Before baseline, the NRTI backbone included tenofovir disoproxil fumarate in the majority of patients [n " 217 (81.6%)]. Treatment failures (n =46): -9 virological failures -16 adverse events -9 withdrawal of consent -7 lost to follow-up -5 other reasons 9 patients excluded before randomization: -3 with HIV-RNA >50 copies/mL -2 not treated with ATV/RTV from >3 months -2 withdrew consent before randomization -1 investigator decision -1 lost to follow-up Figure 1 . Flow chart showing patient allocation throughout the study and main study outcomes. ATV, atazanavir; RTV, ritonavir; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate; FTC, emtricitabine; RAL, raltegravir.
Switch to atazanavir/ritonavir plus lamivudine over 96 weeks JAC At baseline, the two arms were well balanced for the main characteristics (Table 1) .
Efficacy analysis
At 96 weeks, in the ITT-e population, patients free of treatment failure numbered 103/133 (77.4%, 95% CI 70.3/84.5) in the atazanavir/ritonavir ! lamivudine arm and 87/133 (65.4%, 95% CI 57.3/73.5) in the atazanavir/ritonavir ! 2NRTI arm (difference atazanavir/ritonavir ! lamivudine minus atazanavir/ritonavir ! 2NRTI !12.0%, 95% CI !1.2/!22.8, P " 0.030) ( Figure 2 ). Similar results were observed in the PP population: 102/131 (77.9%, 95% CI 70.8/85.0) patients in the atazanavir/ritonavir ! lamivudine arm compared with 84/129 (65.1%, 95% CI 56.9/73.3) patients in the atazanavir/ritonavir ! 2NRTI arm were free of treatment failure (difference between arms !12.8%, 95% CI !1.9%/ !23.7%, P " 0.023).
These results fulfil the predefined non-inferiority criteria and indicate superior efficacy of switching to atazanavir/ritonavir ! lamivudine over continuing atazanavir/ritonavir ! 2NRTI.
The 96 week snapshot analysis also confirmed the superiority of switching to atazanavir/ritonavir ! lamivudine. In the ITT-e population, 103/133 patients (77.4%, 95% CI 70.3/84.5) in the atazanavir/ritonavir ! lamivudine arm versus 85/133 in the atazanavir/ritonavir ! 2NRTI arm (63.9%, 95% CI 55.7/72.1) achieved treatment success (difference between arms !13.5%, 95% CI !2.7/!24.3, P " 0.015). In the PP population, treatment success was achieved in 102/131 patients (77.9%, 95% CI 70.8/85.0) in the atazanavir/ritonavir ! lamivudine arm versus 82/129 in the atazanavir/ritonavir ! 2NRTI arm (63.6%, 95% CI 55.3/71.9) (difference between arms !14.3%, 95% CI !3.4/!25.2, P " 0.011) ( Figure 2 ).
Detailed causes of treatment failure are reported in Table 2 . As reported, during the first 48 weeks, there were two and six virological failures in the atazanavir/ritonavir ! lamivudine arm and the atazanavir/ritonavir ! 2NRTI arm, respectively; 8 between weeks 49 and 96, three additional virological failures were observed with atazanavir/ritonavir ! 2NRTI and none with atazanavir/ritonavir ! lamivudine. Therefore, at week 96 there were more virological failures in the triple therapy arm [n " 9 (6.8%)] compared with the dual therapy arm [n " 2 (1.5%), P " 0.060] (see Table S1 , available as Supplementary data at JAC Online, for details). Nine of 11 (81.8%) virological failures were successfully genotyped, both failures of the atazanavir/ritonavir ! lamivudine Two patients treated with zidovudine ! 3TC and one patient treated with didanosine ! 3TC. c One patient treated with zidovudine ! 3TC, one patient treated with TDF ! ABC and one patient treated with no NRTI backbone (treated with atazanavir/ritonavir ! raltegravir, major protocol deviation). Fabbiani et al. arm and 7/9 of the atazanavir/ritonavir ! 2NRTI arm: no significant resistance to any of the ongoing drugs was detected. Plasma samples for measurement of atazanavir levels at failure were available in 9/11 patients (2/2 in atazanavir/ritonavir ! lamivudine and 7/9 in the atazanavir/ritonavir ! 2NRTI). Undetectable atazanavir levels (,0.05 mg/L) were found in 1/2 (50%) and 3/7 (42.9%) plasma samples in the dual-therapy arm and the triple-therapy arm, respectively; in the remaining patients, the atazanavir concentration was above the suggested mid-dosing interval or trough concentration efficacy cut-off. 19, 20 Patients showing viral blips not leading to virological failure or treatment discontinuation were less frequently found in the dual-therapy arm, but the difference with the comparator arm was not statistically significant [n " 11 (8.3%) in the atazanavir/ ritonavir ! lamivudine arm and n " 20 (15.0%) in the atazanavir/ ritonavir ! 2NRTI arm, P " 0.085].
The proportion of treatment failure due to potentially treatment-related or not-treatment-related adverse events was similar in both arms.
HIV-DNA levels
To monitor changes in the magnitude of the HIV-1 cellular reservoir, blood-associated HIV-DNA levels were quantified both at baseline and at week 96 in a subset of 140 patients. Mean baseline HIV-DNA levels (log 10 copies/10 6 leucocytes) were comparable in the atazanavir/ritonavir ! lamivudine arm (2.42, 95% CI 2.32/2.54) and the atazanavir/ritonavir ! 2NRTI arm (2.37, 95% CI 2.24/2.51) (P " 0.570). Outcomes at 48 weeks have been presented elsewhere. 21 At 96 weeks, a significant decrease from baseline in HIV-DNA (log 10 copies/10 6 leucocytes) was observed in both arms: #0.15 (95% CI #0.23/#0.07, P , 0.001) in the dualtherapy arm versus #0.18 (95% CI #0.27/#0.08, P , 0.001) in the control arm, without significant differences between the two arms (P " 0.703).
Clinical adverse events
The proportion of patients with at least one clinical adverse event of any grade did not differ between arms and there were no significant differences regarding the types of events, although the atazanavir/ritonavir ! 2NRTI arm tended to show a higher number of renal adverse events (Table 3) . Most adverse events were mild to moderate.
There were 18 grade 3 or 4 clinical adverse events: 9 per arm, but only 3 were considered treatment related (see Table 3 footnotes for details). Two sudden deaths, probably from cardiac disease, occurred in the atazanavir/ritonavir ! lamivudine arm, both were not considered treatment related. Two malignant cancers were diagnosed during the study in each study arm (thyroid carcinoma and melanoma in the atazanavir/ritonavir ! lamivudine arm; Figure 2 . Proportion of patients without treatment failure at week 96 (bottom) and differences between the two arms (top). ATV, atazanavir; RTV, ritonavir; 3TC, lamivudine; S " F, switch equal to failure. Switch to atazanavir/ritonavir plus lamivudine over 96 weeks JAC abdominal cancer and prostate adenocarcinoma in the atazanavir/ ritonavir ! 2NRTI arm). Overall, eight renal colics occurred during 96 weeks (two in the atazanavir/ritonavir ! lamivudine arm and six in the atazanavir/ritonavir ! 2NRTI arm); these led to treatment discontinuation in five cases (two in the atazanavir/ritonavir ! lamivudine arm and three in the atazanavir/ritonavir ! 2NRTI arm).
Laboratory toxicity and evolution of laboratory parameters
A significantly higher number of patients randomized to atazanavir/ritonavir ! lamivudine showed at least one grade 3 or 4 laboratory adverse event (79.9% versus 67.7% in the triple-therapy arm, P " 0.026) ( Table 4 ). This excess was mainly attributable to a higher frequency of hyperbilirubinemia (66.9% versus 50.4%, P " 0.006) and hypertriglyceridaemia (6.8% versus 1.5%, P " 0.031) in the dual-therapy arm. However, no patient discontinued the regimen for grade 3 or 4 laboratory adverse events. Indeed, grade 1 or 2 laboratory adverse events led to treatment discontinuation in two (1.5%) patients in the atazanavir/ritonavir ! lamivudine arm (one grade 2 hypertriglyceridaemia, one grade 1 creatinine increase) and five (3.8%) patients in the atazanavir/ritonavir ! 2NRTI arm (one grade 2 hyperbilirubinemia, three grade 1 creatinine increase and one grade 1 proteinuria) (P " 0.447). The evolution of CD4 and serum biochemical parameters from baseline to 96 weeks is illustrated in Figure 3 . Mean changes in CD4 count did not differ between arms (!77 cells/mm 3 with atazanavir/ ritonavir ! lamivudine versus !49 cells/mm 3 with atazanavir/ ritonavir ! 2NRTI, P " 0.306). Mean changes in total cholesterol levels were !16 mg/dL in the atazanavir/ritonavir ! lamivudine arm and !0 mg/dL in the atazanavir/ritonavir ! 2NRTI arm (P " 0.002), with a concomitant increase in LDL cholesterol (!13 mg/dL with atazanavir/ritonavir ! lamivudine versus !4 mg/dL with atazanavir/ritonavir ! 2NRTI, P " 0.092) and HDL cholesterol (!5 mg/dL with atazanavir/ritonavir ! lamivudine versus !0 mg/dL with atazanavir/ritonavir ! 2NRTI, P " 0.002); as a result, modifications of total/HDL cholesterol (!3.1 versus !0.7, P " 0.361) and HDL/LDL cholesterol (0 versus #0.1, P " 0.730) ratios from baseline to 96 weeks did not differ between arms. At 96 weeks, renal function showed a significant improvement in the atazanavir/ritonavir ! lamivudine versus the atazanavir/ritonavir ! 2NRTI arm with a mean change from baseline eGFR MDRD . Conversely, a slight increase in total bilirubin levels was observed in the dual-therapy arm (!0.2 versus #0.1 mg/dL, P " 0.039).
Neurocognitive performance
Neurocognitive data at 96 weeks were available for 107 patients (40.2% on the total), 56 in the study arm and 51 in the control arm. At baseline, patients in the two arms did not differ in terms of Values are expressed as n (%). Grade 3-4 clinical adverse events: nine in the dual-therapy arm [two sudden deaths (probably cardiac), thyroid carcinoma, melanoma, atrial fibrillation, bronchitis, asthma, biliary colic and pancreatitis; the last two events were considered treatment related] and nine in the triple-therapy arm (abdominal cancer, prostate adenocarcinoma, pneumonia, radiculitis, traumatic tibia fracture, finger amputation, pregnancy, cervicitis and renal colic; the last event was considered treatment related). Fabbiani et al.
their main characteristics (data not shown) and showed a comparable proportion of cognitive impairment (10.7% in the atazanavir/ ritonavir ! lamivudine arm versus 21.7% in the atazanavir/ ritonavir ! 2NRTI arm, all with a profile of asymptomatic cognitive impairment, 16 P " 0.185). At 96 weeks, the two groups confirmed no difference in the prevalence of cognitive impairment (14.3% versus 13.7%, respectively, P " 1.000). Analysing each arm separately, both groups confirmed no change in the prevalence of cognitive impairment at 96 weeks in comparison with baseline (atazanavir/ritonavir ! lamivudine arm: 14.3% versus 10.7%, P " 0.625; atazanavir/ritonavir ! 2NRTI arm: 13.7% versus 21.7%, P " 0.219).
Bone health and body fat distribution
Bone mineral density, body fat distribution (as measured by DEXA scan) and biomarkers of bone metabolism were available at baseline and 96 weeks for 91 (34.2%) patients (52 in the atazanavir/ritonavir ! lamivudine arm and 39 in the atazanavir/ ritonavir ! 2NRTI arm). At baseline, bone loss at any site (in terms of osteopenia or osteoporosis) was diagnosed in 61.5% (n " 56) of patients, of which 34/52 (65.4%) were in the atazanavir/ritonavir ! lamivudine arm and 22/39 (56.4%) were in the atazanavir/ ritonavir ! 2NRTI arm (P " 0.384).
At 96 weeks, we observed a significantly higher increase in lumbar spine bone mineral density in dual therapy (mean change versus baseline !4.2% versus #2.5% in the triple-therapy arm, P " 0.021), with no differences in total hip and femoral neck bone mineral density between arms (Table S2) . Evaluating bone biomarkers, a significant reduction in parathyroid hormone levels was observed in the atazanavir/ritonavir ! lamivudine arm (#9.4 versus !0.9 pg/mL in the atazanavir/ritonavir ! 2NRTI arm, P " 0.008); no significant between-arm differences were observed for the other bone biomarkers.
Exploring body fat distribution, at 96 weeks no significant differences between the two arms were observed in terms of change in limb or trunk fat and lean mass (Table S2) .
Adherence
During the study, adherence data were provided by 254 (95.5%) patients [130 (97.7%) in the atazanavir/ritonavir ! lamivudine arm and 124 (93.2%) in the atazanavir/ritonavir ! 2NRTI arm, P " 0.137]. At baseline, adherence was similar in the two arms [mean: 86% (SD 18) in the atazanavir/ritonavir ! lamivudine arm and 88% (SD 14) in the atazanavir/ritonavir ! 2NRTI arm, P " 0.306]. During the entire follow-up, no significant differences were observed in terms of adherence levels at any study visit [mean change versus baseline at 96 weeks: !2% (SD 18) in the atazanavir/ritonavir ! lamivudine arm and #1% (SD 15) in the atazanavir/ritonavir ! 2NRTI arm, P " 0.312].
Discussion
Studies investigating a treatment switch to dual therapy with a boosted PI plus lamivudine in virologically suppressed HIVinfected patients have shown promising results, 5, 8, 9 but few data are available about the efficacy of this strategy over the long Switch to atazanavir/ritonavir plus lamivudine over 96 weeks JAC term. 7, 10 Moreover, real benefits in terms of reduced toxicity have not been completely demonstrated and concerns remain about reduced activity in sanctuary sites (e.g. the CNS).
At 96 weeks, the results of the ATLAS-M trial confirm the noninferiority of treatment simplification to atazanavir/ritonavir ! lamivudine versus continuing an atazanavir/ritonavir-based triple therapy in virologically suppressed patients. Moreover, a post hoc superiority of this dual therapy was demonstrated by all types of analyses performed. This result was driven by several factors, including lower discontinuation rates for adverse events (both treatment and not treatment related), less frequent withdrawal of consent but also, most importantly, by lower rates of virological failure in the atazanavir/ritonavir ! lamivudine arm. Only two virological failures (one of which occurred at baseline before the treatment switch) were observed with the dual therapy during the first 48 weeks and no further virological failure occurred thereafter. Moreover, no emerging HIV-1 drug resistance was observed at failure in both arms. These results confirm the efficacy over the long term of treatment simplification to atazanavir/ritonavir ! lamivudine in virologically suppressed patients with very low risk of virological failure and absence of resistance in the case of failure.
Regarding tolerability, patients switched to atazanavir/ritonavir ! lamivudine showed a significant recovery of eGFR when compared with those continuing triple therapy, suggesting that this regimen could halt the deterioration of renal function. This observation can be ascribed to the discontinuation of tenofovir disoproxil fumarate in the majority of patients randomized to the dual-therapy arm. Whether a similar result could be obtained with a switch to a tenofovir alafenamide-containing backbone remains to be determined as no studies have yet directly compared tenofovir alafenamide with dual therapies. 22 The discontinuation of tenofovir disoproxil fumarate could also explain the improvements in lumbar spine bone mineral density 23 observed in the atazanavir/ritonavir ! lamivudine arm, while patients treated with atazanavir/ritonavir ! 2NRTI worsened; as expected after tenofovir disoproxil fumarate discontinuation, 24 we also observed a reduction in parathyroid hormone levels in the dual-therapy arm, which might have been translated into a lower bone resorption.
Patients switched to dual therapy showed a slight increase in total cholesterol but also HDL cholesterol; this can be ascribed to the discontinuation of tenofovir disoproxil fumarate, which has a known lipid-lowering effect. 25, 26 However, total/HDL cholesterol and HDL/LDL cholesterol ratios remained unchanged and, as a consequence, the impact on the cardiovascular risk is expected to be negligible.
In the dual-therapy arm, we observed a higher proportion of patients developing grade 3 or 4 increases in bilirubin and triglyceride levels, but this did not impact the tolerability of the regimens since treatment discontinuations for laboratory adverse events were similar between arms. A potential explanation for higher bilirubin levels in the dual-therapy arm could be an increase in atazanavir plasma concentration due to tenofovir disoproxil fumarate discontinuation, which occurred in the majority of patients, as suggested by drug-drug interaction studies. 27 A supposed drawback of dual therapy is potential concern about reduced efficacy in controlling viral replication in sanctuary sites. To assess this issue in ATLAS-M, total HIV-DNA level, a surrogate marker of viral replication in reservoirs, 28 was measured during the study. At 96 weeks, we observed a significant decrease in total HIV-DNA levels in both arms, without any significant between-arm differences. This observation confirms results obtained at 48 weeks 21 and offers a degree of reassurance about the ability of this dual regimen in controlling viral replication in reservoirs over the long term.
Another concern about simplification to dual therapies is the potential for inadequate drug activity in the CNS. Importantly, in our study no significant difference in the prevalence of neurocognitive impairment was observed between the two study arms at 96 weeks, suggesting a CNS-safe profile of simplification to atazanavir/ritonavir ! lamivudine, at least in the medium term, in subjects with stable plasma viral load control and without symptomatic neurocognitive impairment.
Treatment simplification to atazanavir/ritonavir ! lamivudine in virologically suppressed patients has also been investigated by the SALT trial, which demonstrated non-inferior efficacy (although not superiority) at 96 weeks of the dual therapy over an atazanavir/ritonavir-based triple therapy, without any benefit in terms of tolerability. 10 The SALT and ATLAS-M trials were slightly different regarding study design and this could explain why superior efficacy and better renal tolerability of atazanavir/ritonavir ! lamivudine were not shown in the SALT trial. The SALT trial enrolled patients on any ART regimen and allowed switching of the NRTI backbone at baseline in those with tolerability issues, thus efficacy results relied also on tolerability of drugs not previously taken by patients. In the ATLAS-M trial, all patients were treated with atazanavir/ritonavir ! 2NRTI before baseline, and therefore those randomized to dual therapy simply removed an NRTI from their standard triple-therapy regimen. In this way, the study design of the ATLAS-M trial more accurately reflects what happens when an NRTI drug is removed from a standard triple-therapy regimen, both in terms of efficacy and tolerability. Some limitations should be acknowledged when interpreting the results of our study. Since this is an open-label study, physicians could have been more prone to discontinue treatment if toxicity occurred and this could have partly influenced the main outcome. However, this potential bias does not influence virological outcome, which was favourable with dual therapy. It should also be emphasized that patients included in the ATLAS-M study were accurately selected according to strict inclusion and exclusion criteria, meaning that results cannot be generalized to all HIV-infected patients. In particular, this dual regimen should not be prescribed to patients without stable virological suppression, with a low CD4 count, with previous episodes of virological failure or with coinfection with HBV, as for all other tenofovir-sparing regimens.
In conclusion, in the ATLAS-M trial, the safety and efficacy of treatment simplification to atazanavir/ritonavir ! lamivudine in virologically suppressed patients were confirmed over 96 weeks, with a post hoc superiority of dual therapy over a standard tripletherapy regimen. A sustained benefit in terms of preserved renal function and improvement in lumbar spine bone mineral density was observed, without other significant laboratory concerns. Of note, no concerns about the efficacy of dual therapy in sanctuary sites emerged during the 96 weeks of the trial, as demonstrated by the constant decrease in total blood HIV-DNA levels and by the evolution of cognitive performance. These promising efficacy and safety data of atazanavir/ritonavir ! lamivudine, Fabbiani et al. together with a potential for substantial cost reduction of ART, 29, 30 especially if generic drugs are used, make this regimen a suitable option for treatment simplification.
